January 4, 2019 by Chain Drug Review
Amneal Pharmaceuticals, David Buchen, Inc., Robert Stewart
Supplier News
BRIDGEWATER, N.J. — Amneal Pharmaceuticals, Inc. has appointed David Buchen to the newly expanded role of senior vice president, chief legal officer and corporate secretary, reporting to oresident and chief executive officer Robert Stewart. Buchen will be responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to
December 20, 2017 by Chain Drug Review
Allergan, Amneal Pharmaceuticals, Amneal-Impax merger, Brent Saunders, Chintu Patel, Chirag Patel, Impax Laboratories, Paul Bisaro, Robert Stewart, Wayne Swanton
Business, Supplier News
NEW YORK — Merger partners Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have tabbed Robert Stewart, executive vice president and chief operating officer of Allergan plc, to lead the combined company. Plans call for Stewart to join Amneal as president effective Jan. 25. After Amneal and Impax finalize their merger, announced in mid-October, he will
May 3, 2016 by Chain Drug Review
Allergan, guaifenesin, John Hendrickson, Mucinex DM, Perrigo, Reckitt Benckiser, Robert Stewart
Pharmacy, Supplier News
DUBLIN, Ireland — Perrigo Co. and Allergan plc have rolled out guaifenesin 1,200-mg and dextromethorphan HBr 60-mg extended-release tablets, a combination expectorant and cough suppressant. The companies said Tuesday that the product marks the first over-the-counter store-brand equivalent to Mucinex DM 1,200-mg ER tablets from Reckitt Benckiser (RB) for retail and wholesale customers. First shipments
May 3, 2016 by Chain Drug Review
Allergan, AstraZeneca, generic version of Crestor, Robert Stewart, rosuvastatin calcium
Pharmacy, Supplier News
DUBLIN, Ireland — Allergan plc has received final approval from the Food and Drug Administration for rosuvastatin calcium tablets, a cholesterol-lowering medication. The company said its rosuvastatin calcium product comes in dosages of 5 mg, 10 mg, 20 mg and 40 mg and is a generic version of Crestor tablets from AstraZeneca. Allergan noted that
March 25, 2016 by Chain Drug Review
Allergan, guaifenesin extended-release tablets, Joseph Papa, Mucinex, Perrgio, Robert Stewart
Pharmacy, Supplier News
DUBLIN, Ireland — Perrigo Co. plc and Allergan plc have begun shipping 1,200-mg guaifenesin extended-release tablets, an expectorant, to retail and wholesale customers. The companies said this week that the over-the-counter product, a generic equivalent to Reckitt Benckiser’s Mucinex ER tablets (guaifenesin 1,200 mg), is packaged and marketed as store brands or retailer own-label brands. “This
January 4, 2016 by Chain Drug Review
Allergan, Joseph Papa, Mucinex D, Perrigo, Robert Stewart
Pharmacy, Supplier News
DUBLIN, Ireland — Allergan plc and Perrigo Co. plc have launched combination guaifenesin 600-mg and pseudoephedrine HCl 60-mg extended-release tablets to retail and wholesale customers. Allergan and Perrigo said Monday that the initial shipments of the new store-brand product, which began in December, mark a first-to-market achievement for the companies. “This first-to-market launch illustrates the
June 2, 2015 by Chain Drug Review and Chain Drug Review
Actavis, guaifenesin/pseudoephedrine tablets, Joseph Papa, Mucinex D, Perrigo, Reckitt Benckiser, Robert Stewart
Supplier News
DUBLIN, Ireland — Actavis plc and Perrigo Co. plc have been cleared by the Food and Drug Administration to market guaifenesin/pseudoephedrine tablets, an expectorant. The companies said Tuesday that Perrigo is slated to commence shipments to U.S. retail and wholesale customers in time for the cough/cold season. The product will be packaged and marketed under
